Bispecific Antibodies in the Treatment of Hematologic Malignancies

被引：51

作者：

Duell, Johannes ^{[1
]}

Lammers, Philip E. ^{[2
]}

Djuretic, Ivana ^{[3
]}

Chunyk, Allison G. ^{[4
]}

Alekar, Shilpa ^{[4
]}

Jacobs, Ira ^{[5
]}

Gill, Saar ^{[6
,7
]}

机构：

[1] Univ Klinikum Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Baptist Canc Ctr, Memphis, TN USA

[3] Pfizer Inc, San Francisco, CA USA

[4] Pfizer Inc, La Jolla, CA USA

[5] Pfizer Inc, New York, NY 10017 USA

[6] Univ Penn, Blood & Marrow Transplantat Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 106卷 / 04期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; CAR T-CELLS; CLINICAL DEVELOPMENT; BLINATUMOMAB; THERAPY; RESISTANCE; DEPLETION; EFFICACY; SAFETY;

D O I：

10.1002/cpt.1396

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.

引用

页码：781 / 791

页数：11

共 50 条

[31] PROPHYLACTIC ANTIFUNGAL TREATMENT IN HEMATOLOGIC MALIGNANCIES
Senol, Esin
LEUKEMIA RESEARCH, 2014, 38 : S11 - S11
[32] THE ROLE OF INTERFERONS IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
GUTTERMAN, JU
SEMINARS IN HEMATOLOGY, 1988, 25 (03) : 3 - 8
[33] Biomimetic Nanoparticles for the Treatment of Hematologic Malignancies
Powsner, Emily H.
Harris, Jenna C.
Day, Emily S.
ADVANCED NANOBIOMED RESEARCH, 2021, 1 (04):
[34] Imatinib mesylate in the treatment of hematologic malignancies
Piccaluga, Pier Paolo
Rondoni, Michela
Paolini, Stefania
Rosti, Gianantonio
Martinelli, Giovanni
Baccarani, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (10) : 1597 - 1611
[35] ETOPOSIDE AND PLATINUMS IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
PAPAYANNIS, AG
JOURNAL OF CHEMOTHERAPY, 1993, 5 : 676 - 677
[36] Differentiation induction as a treatment for hematologic malignancies
Miller, WH
Waxman, S
ONCOGENE, 2002, 21 (21) : 3496 - 3506
[37] Improving leukaemia treatment with bispecific antibodies
Crunkhorn, Sarah
NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (07) : 538 - 538
[38] Improving leukaemia treatment with bispecific antibodies
Sarah Crunkhorn
Nature Reviews Drug Discovery, 2023, 22 : 538 - 538
[39] Bispecific Antibodies for the Treatment of Multiple Myeloma
Scott R. Goldsmith
Shawn Streeter
Fahrettin Covut
Current Hematologic Malignancy Reports, 2022, 17 : 286 - 297
[40] Bispecific antibodies for the treatment of breast cancer
Dillon, Patrick M.
Tushir-Singh, Jogender
Lum, Lawrence G.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (08) : 1017 - 1027

← 1 2 3 4 5 →